Global Psoriasis Drug Market

Psoriasis Drug Comprehensive Study by Type (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies), Application (Packaging, Automotive, Building and Construction), Route of Administration (Oral, Parenteral, Topical), Distribution Channel (Wholesalers, Distributors, Retailers), End User (Hospital, Drugs Store) Players and Region - Global Market Outlook to 2027

Psoriasis Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Psoriasis drug is used for diagnosis of Psoriasis disease and it is a common disorder of the skin, immune system, and joints that are influenced by genetic and environmental factors. It is used for the diagnosis of psoriasis by using topical treatments, phototherapy, traditional systemic agents, and biological therapies for patients. Psoriasis Drugs can induce psoriasis de novo or induce lesions in previously unaffected skin and can exacerbate psoriasis in a patient already afflicted with psoriasis by treatment resistance or causing flares.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledAbbVie (United States), Johnson & Johnson (United States), Bayer AG (Germany), Galderma S.A.(Switzerland), Bristol-Myers Squibb (United States), Novartis International AG (Switzerland), Pfizer Inc. (United States), Merz Pharma GmbH & Co. KGaA (Germany), Bausch Health Companies Inc. (Canada), LEO Pharma A/S (Denmark) and GlaxoSmithKline plc (United kingdom)


This growth is primarily driven by Increasing Disease Burden and Demand for Psoriasis Drugs in Emerging Economies and Rising use of Combination Therapies Globally.

Globally, a noticeable market trend is evident The growing use of Interleukin Inhibitors The Pharmaceuticals sector in the Asia Pacific region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as AbbVie (United States), Johnson & Johnson (United States), Bayer AG (Germany), Galderma S.A.(Switzerland), Bristol-Myers Squibb (United States), Novartis International AG (Switzerland), Pfizer Inc. (United States), Merz Pharma GmbH & Co. KGaA (Germany), Bausch Health Companies Inc. (Canada), LEO Pharma A/S (Denmark) and GlaxoSmithKline plc (United kingdom), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. Market companies are using cutting-edge techniques, like the use of biotechnology in the creation of therapies, to improve the efficacy of treatment. As a result, several major firms are spending on R&D and planning to release a tonne of upcoming items.

Key Developments in the Market:
On 1st September 2022, Arcutis launch a new campaign to “expose” the skin disease, with a fresh FDA nod for Zoryve in hand. With the new campaign, Arcutis wants to address “the value of having a support network".


Influencing Trend:
The growing use of Interleukin Inhibitors

Market Growth Drivers:
Increasing Disease Burden and Demand for Psoriasis Drugs in Emerging Economies and Rising use of Combination Therapies Globally

Challenges:
Lack of Awareness of benefits of the Psoriasis Drug

Restraints:
Strict Government Regulations and FDA Regulations and High Medical Cost for Patients Associated with the Treatment of Psoriasis

Opportunities:
Increase in Psoriasis Research and Pipeline Drugs

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Psoriasis Drug Market
- Analysis about New Entrants in Psoriasis Drug Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Psoriasis Drug Study Sheds Light on
— The Psoriasis Drug Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Psoriasis Drug industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Psoriasis Drug industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Biologic Drugs
  • Small Molecule Systemic Drugs
  • Tropical Therapies
By Application
  • Packaging
  • Automotive
  • Building and Construction
By Route of Administration
  • Oral
  • Parenteral
  • Topical

By Distribution Channel
  • Wholesalers
  • Distributors
  • Retailers

By End User
  • Hospital
  • Drugs Store

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Disease Burden and Demand for Psoriasis Drugs in Emerging Economies
      • 3.2.2. Rising use of Combination Therapies Globally
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness of benefits of the Psoriasis Drug
    • 3.4. Market Trends
      • 3.4.1. The growing use of Interleukin Inhibitors
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Psoriasis Drug, by Type, Application, Route of Administration, Distribution Channel, End User and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Psoriasis Drug (Value)
      • 5.2.1. Global Psoriasis Drug by: Type (Value)
        • 5.2.1.1. Biologic Drugs
        • 5.2.1.2. Small Molecule Systemic Drugs
        • 5.2.1.3. Tropical Therapies
      • 5.2.2. Global Psoriasis Drug by: Application (Value)
        • 5.2.2.1. Packaging
        • 5.2.2.2. Automotive
        • 5.2.2.3. Building and Construction
      • 5.2.3. Global Psoriasis Drug by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Parenteral
        • 5.2.3.3. Topical
      • 5.2.4. Global Psoriasis Drug by: Distribution Channel (Value)
        • 5.2.4.1. Wholesalers
        • 5.2.4.2. Distributors
        • 5.2.4.3. Retailers
      • 5.2.5. Global Psoriasis Drug by: End User (Value)
        • 5.2.5.1. Hospital
        • 5.2.5.2. Drugs Store
      • 5.2.6. Global Psoriasis Drug Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Australia
          • 5.2.6.2.6. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Psoriasis Drug (Volume)
      • 5.3.1. Global Psoriasis Drug by: Type (Volume)
        • 5.3.1.1. Biologic Drugs
        • 5.3.1.2. Small Molecule Systemic Drugs
        • 5.3.1.3. Tropical Therapies
      • 5.3.2. Global Psoriasis Drug by: Application (Volume)
        • 5.3.2.1. Packaging
        • 5.3.2.2. Automotive
        • 5.3.2.3. Building and Construction
      • 5.3.3. Global Psoriasis Drug by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Parenteral
        • 5.3.3.3. Topical
      • 5.3.4. Global Psoriasis Drug by: Distribution Channel (Volume)
        • 5.3.4.1. Wholesalers
        • 5.3.4.2. Distributors
        • 5.3.4.3. Retailers
      • 5.3.5. Global Psoriasis Drug by: End User (Volume)
        • 5.3.5.1. Hospital
        • 5.3.5.2. Drugs Store
      • 5.3.6. Global Psoriasis Drug Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Australia
          • 5.3.6.2.6. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Psoriasis Drug (Price)
      • 5.4.1. Global Psoriasis Drug by: Type (Price)
  • 6. Psoriasis Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson & Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bayer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Galderma S.A.(Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol-Myers Squibb (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merz Pharma GmbH & Co. KGaA (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bausch Health Companies Inc. (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. LEO Pharma A/S (Denmark)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. GlaxoSmithKline plc (United kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Psoriasis Drug Sale, by Type, Application, Route of Administration, Distribution Channel, End User and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Psoriasis Drug (Value)
      • 7.2.1. Global Psoriasis Drug by: Type (Value)
        • 7.2.1.1. Biologic Drugs
        • 7.2.1.2. Small Molecule Systemic Drugs
        • 7.2.1.3. Tropical Therapies
      • 7.2.2. Global Psoriasis Drug by: Application (Value)
        • 7.2.2.1. Packaging
        • 7.2.2.2. Automotive
        • 7.2.2.3. Building and Construction
      • 7.2.3. Global Psoriasis Drug by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Parenteral
        • 7.2.3.3. Topical
      • 7.2.4. Global Psoriasis Drug by: Distribution Channel (Value)
        • 7.2.4.1. Wholesalers
        • 7.2.4.2. Distributors
        • 7.2.4.3. Retailers
      • 7.2.5. Global Psoriasis Drug by: End User (Value)
        • 7.2.5.1. Hospital
        • 7.2.5.2. Drugs Store
      • 7.2.6. Global Psoriasis Drug Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Australia
          • 7.2.6.2.6. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Psoriasis Drug (Volume)
      • 7.3.1. Global Psoriasis Drug by: Type (Volume)
        • 7.3.1.1. Biologic Drugs
        • 7.3.1.2. Small Molecule Systemic Drugs
        • 7.3.1.3. Tropical Therapies
      • 7.3.2. Global Psoriasis Drug by: Application (Volume)
        • 7.3.2.1. Packaging
        • 7.3.2.2. Automotive
        • 7.3.2.3. Building and Construction
      • 7.3.3. Global Psoriasis Drug by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Parenteral
        • 7.3.3.3. Topical
      • 7.3.4. Global Psoriasis Drug by: Distribution Channel (Volume)
        • 7.3.4.1. Wholesalers
        • 7.3.4.2. Distributors
        • 7.3.4.3. Retailers
      • 7.3.5. Global Psoriasis Drug by: End User (Volume)
        • 7.3.5.1. Hospital
        • 7.3.5.2. Drugs Store
      • 7.3.6. Global Psoriasis Drug Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Australia
          • 7.3.6.2.6. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Psoriasis Drug (Price)
      • 7.4.1. Global Psoriasis Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Psoriasis Drug: by Type(USD Million)
  • Table 2. Psoriasis Drug Biologic Drugs , by Region USD Million (2016-2021)
  • Table 3. Psoriasis Drug Small Molecule Systemic Drugs , by Region USD Million (2016-2021)
  • Table 4. Psoriasis Drug Tropical Therapies , by Region USD Million (2016-2021)
  • Table 5. Psoriasis Drug: by Application(USD Million)
  • Table 6. Psoriasis Drug Packaging , by Region USD Million (2016-2021)
  • Table 7. Psoriasis Drug Automotive , by Region USD Million (2016-2021)
  • Table 8. Psoriasis Drug Building and Construction , by Region USD Million (2016-2021)
  • Table 9. Psoriasis Drug: by Route of Administration(USD Million)
  • Table 10. Psoriasis Drug Oral , by Region USD Million (2016-2021)
  • Table 11. Psoriasis Drug Parenteral , by Region USD Million (2016-2021)
  • Table 12. Psoriasis Drug Topical , by Region USD Million (2016-2021)
  • Table 13. Psoriasis Drug: by Distribution Channel(USD Million)
  • Table 14. Psoriasis Drug Wholesalers , by Region USD Million (2016-2021)
  • Table 15. Psoriasis Drug Distributors , by Region USD Million (2016-2021)
  • Table 16. Psoriasis Drug Retailers , by Region USD Million (2016-2021)
  • Table 17. Psoriasis Drug: by End User(USD Million)
  • Table 18. Psoriasis Drug Hospital , by Region USD Million (2016-2021)
  • Table 19. Psoriasis Drug Drugs Store , by Region USD Million (2016-2021)
  • Table 20. South America Psoriasis Drug, by Country USD Million (2016-2021)
  • Table 21. South America Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 22. South America Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 23. South America Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 24. South America Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 25. South America Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 26. Brazil Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 27. Brazil Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 28. Brazil Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 29. Brazil Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 30. Brazil Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 31. Argentina Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 32. Argentina Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 33. Argentina Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 34. Argentina Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 35. Argentina Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 36. Rest of South America Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 37. Rest of South America Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 38. Rest of South America Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 39. Rest of South America Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 40. Rest of South America Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 41. Asia Pacific Psoriasis Drug, by Country USD Million (2016-2021)
  • Table 42. Asia Pacific Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 43. Asia Pacific Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 44. Asia Pacific Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 45. Asia Pacific Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 46. Asia Pacific Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 47. China Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 48. China Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 49. China Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 50. China Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 51. China Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 52. Japan Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 53. Japan Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 54. Japan Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 55. Japan Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 56. Japan Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 57. India Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 58. India Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 59. India Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 60. India Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 61. India Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 62. South Korea Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 63. South Korea Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 64. South Korea Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 65. South Korea Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 66. South Korea Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 67. Australia Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 68. Australia Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 69. Australia Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 70. Australia Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 71. Australia Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 72. Rest of Asia-Pacific Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 73. Rest of Asia-Pacific Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 74. Rest of Asia-Pacific Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 75. Rest of Asia-Pacific Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 76. Rest of Asia-Pacific Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 77. Europe Psoriasis Drug, by Country USD Million (2016-2021)
  • Table 78. Europe Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 79. Europe Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 80. Europe Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 81. Europe Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 82. Europe Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 83. Germany Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 84. Germany Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 85. Germany Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 86. Germany Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 87. Germany Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 88. France Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 89. France Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 90. France Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 91. France Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 92. France Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 93. Italy Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 94. Italy Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 95. Italy Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 96. Italy Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 97. Italy Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 98. United Kingdom Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 99. United Kingdom Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 100. United Kingdom Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 101. United Kingdom Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 102. United Kingdom Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 103. Netherlands Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 104. Netherlands Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 105. Netherlands Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 106. Netherlands Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 107. Netherlands Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 108. Rest of Europe Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 109. Rest of Europe Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 110. Rest of Europe Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 111. Rest of Europe Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 112. Rest of Europe Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 113. MEA Psoriasis Drug, by Country USD Million (2016-2021)
  • Table 114. MEA Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 115. MEA Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 116. MEA Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 117. MEA Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 118. MEA Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 119. Middle East Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 120. Middle East Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 121. Middle East Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 122. Middle East Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 123. Middle East Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 124. Africa Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 125. Africa Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 126. Africa Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 127. Africa Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 128. Africa Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 129. North America Psoriasis Drug, by Country USD Million (2016-2021)
  • Table 130. North America Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 131. North America Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 132. North America Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 133. North America Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 134. North America Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 135. United States Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 136. United States Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 137. United States Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 138. United States Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 139. United States Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 140. Canada Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 141. Canada Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 142. Canada Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 143. Canada Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 144. Canada Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 145. Mexico Psoriasis Drug, by Type USD Million (2016-2021)
  • Table 146. Mexico Psoriasis Drug, by Application USD Million (2016-2021)
  • Table 147. Mexico Psoriasis Drug, by Route of Administration USD Million (2016-2021)
  • Table 148. Mexico Psoriasis Drug, by Distribution Channel USD Million (2016-2021)
  • Table 149. Mexico Psoriasis Drug, by End User USD Million (2016-2021)
  • Table 150. Psoriasis Drug Sales: by Type(K Units)
  • Table 151. Psoriasis Drug Sales Biologic Drugs , by Region K Units (2016-2021)
  • Table 152. Psoriasis Drug Sales Small Molecule Systemic Drugs , by Region K Units (2016-2021)
  • Table 153. Psoriasis Drug Sales Tropical Therapies , by Region K Units (2016-2021)
  • Table 154. Psoriasis Drug Sales: by Application(K Units)
  • Table 155. Psoriasis Drug Sales Packaging , by Region K Units (2016-2021)
  • Table 156. Psoriasis Drug Sales Automotive , by Region K Units (2016-2021)
  • Table 157. Psoriasis Drug Sales Building and Construction , by Region K Units (2016-2021)
  • Table 158. Psoriasis Drug Sales: by Route of Administration(K Units)
  • Table 159. Psoriasis Drug Sales Oral , by Region K Units (2016-2021)
  • Table 160. Psoriasis Drug Sales Parenteral , by Region K Units (2016-2021)
  • Table 161. Psoriasis Drug Sales Topical , by Region K Units (2016-2021)
  • Table 162. Psoriasis Drug Sales: by Distribution Channel(K Units)
  • Table 163. Psoriasis Drug Sales Wholesalers , by Region K Units (2016-2021)
  • Table 164. Psoriasis Drug Sales Distributors , by Region K Units (2016-2021)
  • Table 165. Psoriasis Drug Sales Retailers , by Region K Units (2016-2021)
  • Table 166. Psoriasis Drug Sales: by End User(K Units)
  • Table 167. Psoriasis Drug Sales Hospital , by Region K Units (2016-2021)
  • Table 168. Psoriasis Drug Sales Drugs Store , by Region K Units (2016-2021)
  • Table 169. South America Psoriasis Drug Sales, by Country K Units (2016-2021)
  • Table 170. South America Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 171. South America Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 172. South America Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 173. South America Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 174. South America Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 175. Brazil Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 176. Brazil Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 177. Brazil Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 178. Brazil Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 179. Brazil Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 180. Argentina Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 181. Argentina Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 182. Argentina Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 183. Argentina Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 184. Argentina Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 185. Rest of South America Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 186. Rest of South America Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 187. Rest of South America Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 188. Rest of South America Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 189. Rest of South America Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 190. Asia Pacific Psoriasis Drug Sales, by Country K Units (2016-2021)
  • Table 191. Asia Pacific Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 192. Asia Pacific Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 193. Asia Pacific Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 194. Asia Pacific Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 195. Asia Pacific Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 196. China Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 197. China Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 198. China Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 199. China Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 200. China Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 201. Japan Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 202. Japan Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 203. Japan Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 204. Japan Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 205. Japan Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 206. India Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 207. India Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 208. India Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 209. India Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 210. India Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 211. South Korea Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 212. South Korea Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 213. South Korea Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 214. South Korea Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 215. South Korea Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 216. Australia Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 217. Australia Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 218. Australia Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 219. Australia Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 220. Australia Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 221. Rest of Asia-Pacific Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 222. Rest of Asia-Pacific Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 223. Rest of Asia-Pacific Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 224. Rest of Asia-Pacific Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 225. Rest of Asia-Pacific Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 226. Europe Psoriasis Drug Sales, by Country K Units (2016-2021)
  • Table 227. Europe Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 228. Europe Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 229. Europe Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 230. Europe Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 231. Europe Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 232. Germany Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 233. Germany Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 234. Germany Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 235. Germany Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 236. Germany Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 237. France Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 238. France Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 239. France Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 240. France Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 241. France Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 242. Italy Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 243. Italy Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 244. Italy Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 245. Italy Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 246. Italy Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 247. United Kingdom Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 248. United Kingdom Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 249. United Kingdom Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 250. United Kingdom Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 251. United Kingdom Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 252. Netherlands Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 253. Netherlands Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 254. Netherlands Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 255. Netherlands Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 256. Netherlands Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 257. Rest of Europe Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 258. Rest of Europe Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 259. Rest of Europe Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 260. Rest of Europe Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 261. Rest of Europe Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 262. MEA Psoriasis Drug Sales, by Country K Units (2016-2021)
  • Table 263. MEA Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 264. MEA Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 265. MEA Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 266. MEA Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 267. MEA Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 268. Middle East Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 269. Middle East Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 270. Middle East Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 271. Middle East Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 272. Middle East Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 273. Africa Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 274. Africa Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 275. Africa Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 276. Africa Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 277. Africa Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 278. North America Psoriasis Drug Sales, by Country K Units (2016-2021)
  • Table 279. North America Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 280. North America Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 281. North America Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 282. North America Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 283. North America Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 284. United States Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 285. United States Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 286. United States Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 287. United States Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 288. United States Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 289. Canada Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 290. Canada Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 291. Canada Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 292. Canada Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 293. Canada Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 294. Mexico Psoriasis Drug Sales, by Type K Units (2016-2021)
  • Table 295. Mexico Psoriasis Drug Sales, by Application K Units (2016-2021)
  • Table 296. Mexico Psoriasis Drug Sales, by Route of Administration K Units (2016-2021)
  • Table 297. Mexico Psoriasis Drug Sales, by Distribution Channel K Units (2016-2021)
  • Table 298. Mexico Psoriasis Drug Sales, by End User K Units (2016-2021)
  • Table 299. Psoriasis Drug: by Type(USD/Units)
  • Table 300. Company Basic Information, Sales Area and Its Competitors
  • Table 301. Company Basic Information, Sales Area and Its Competitors
  • Table 302. Company Basic Information, Sales Area and Its Competitors
  • Table 303. Company Basic Information, Sales Area and Its Competitors
  • Table 304. Company Basic Information, Sales Area and Its Competitors
  • Table 305. Company Basic Information, Sales Area and Its Competitors
  • Table 306. Company Basic Information, Sales Area and Its Competitors
  • Table 307. Company Basic Information, Sales Area and Its Competitors
  • Table 308. Company Basic Information, Sales Area and Its Competitors
  • Table 309. Company Basic Information, Sales Area and Its Competitors
  • Table 310. Company Basic Information, Sales Area and Its Competitors
  • Table 311. Psoriasis Drug: by Type(USD Million)
  • Table 312. Psoriasis Drug Biologic Drugs , by Region USD Million (2022-2027)
  • Table 313. Psoriasis Drug Small Molecule Systemic Drugs , by Region USD Million (2022-2027)
  • Table 314. Psoriasis Drug Tropical Therapies , by Region USD Million (2022-2027)
  • Table 315. Psoriasis Drug: by Application(USD Million)
  • Table 316. Psoriasis Drug Packaging , by Region USD Million (2022-2027)
  • Table 317. Psoriasis Drug Automotive , by Region USD Million (2022-2027)
  • Table 318. Psoriasis Drug Building and Construction , by Region USD Million (2022-2027)
  • Table 319. Psoriasis Drug: by Route of Administration(USD Million)
  • Table 320. Psoriasis Drug Oral , by Region USD Million (2022-2027)
  • Table 321. Psoriasis Drug Parenteral , by Region USD Million (2022-2027)
  • Table 322. Psoriasis Drug Topical , by Region USD Million (2022-2027)
  • Table 323. Psoriasis Drug: by Distribution Channel(USD Million)
  • Table 324. Psoriasis Drug Wholesalers , by Region USD Million (2022-2027)
  • Table 325. Psoriasis Drug Distributors , by Region USD Million (2022-2027)
  • Table 326. Psoriasis Drug Retailers , by Region USD Million (2022-2027)
  • Table 327. Psoriasis Drug: by End User(USD Million)
  • Table 328. Psoriasis Drug Hospital , by Region USD Million (2022-2027)
  • Table 329. Psoriasis Drug Drugs Store , by Region USD Million (2022-2027)
  • Table 330. South America Psoriasis Drug, by Country USD Million (2022-2027)
  • Table 331. South America Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 332. South America Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 333. South America Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 334. South America Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 335. South America Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 336. Brazil Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 337. Brazil Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 338. Brazil Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 339. Brazil Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 340. Brazil Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 341. Argentina Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 342. Argentina Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 343. Argentina Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 344. Argentina Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 345. Argentina Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 346. Rest of South America Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 347. Rest of South America Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 348. Rest of South America Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 349. Rest of South America Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 350. Rest of South America Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 351. Asia Pacific Psoriasis Drug, by Country USD Million (2022-2027)
  • Table 352. Asia Pacific Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 353. Asia Pacific Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 354. Asia Pacific Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 355. Asia Pacific Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 356. Asia Pacific Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 357. China Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 358. China Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 359. China Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 360. China Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 361. China Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 362. Japan Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 363. Japan Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 364. Japan Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 365. Japan Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 366. Japan Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 367. India Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 368. India Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 369. India Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 370. India Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 371. India Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 372. South Korea Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 373. South Korea Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 374. South Korea Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 375. South Korea Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 376. South Korea Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 377. Australia Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 378. Australia Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 379. Australia Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 380. Australia Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 381. Australia Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 382. Rest of Asia-Pacific Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 383. Rest of Asia-Pacific Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 384. Rest of Asia-Pacific Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 385. Rest of Asia-Pacific Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 386. Rest of Asia-Pacific Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 387. Europe Psoriasis Drug, by Country USD Million (2022-2027)
  • Table 388. Europe Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 389. Europe Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 390. Europe Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 391. Europe Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 392. Europe Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 393. Germany Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 394. Germany Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 395. Germany Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 396. Germany Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 397. Germany Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 398. France Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 399. France Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 400. France Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 401. France Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 402. France Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 403. Italy Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 404. Italy Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 405. Italy Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 406. Italy Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 407. Italy Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 408. United Kingdom Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 409. United Kingdom Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 410. United Kingdom Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 411. United Kingdom Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 412. United Kingdom Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 413. Netherlands Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 414. Netherlands Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 415. Netherlands Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 416. Netherlands Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 417. Netherlands Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 418. Rest of Europe Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 419. Rest of Europe Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 420. Rest of Europe Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 421. Rest of Europe Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 422. Rest of Europe Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 423. MEA Psoriasis Drug, by Country USD Million (2022-2027)
  • Table 424. MEA Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 425. MEA Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 426. MEA Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 427. MEA Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 428. MEA Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 429. Middle East Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 430. Middle East Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 431. Middle East Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 432. Middle East Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 433. Middle East Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 434. Africa Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 435. Africa Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 436. Africa Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 437. Africa Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 438. Africa Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 439. North America Psoriasis Drug, by Country USD Million (2022-2027)
  • Table 440. North America Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 441. North America Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 442. North America Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 443. North America Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 444. North America Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 445. United States Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 446. United States Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 447. United States Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 448. United States Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 449. United States Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 450. Canada Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 451. Canada Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 452. Canada Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 453. Canada Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 454. Canada Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 455. Mexico Psoriasis Drug, by Type USD Million (2022-2027)
  • Table 456. Mexico Psoriasis Drug, by Application USD Million (2022-2027)
  • Table 457. Mexico Psoriasis Drug, by Route of Administration USD Million (2022-2027)
  • Table 458. Mexico Psoriasis Drug, by Distribution Channel USD Million (2022-2027)
  • Table 459. Mexico Psoriasis Drug, by End User USD Million (2022-2027)
  • Table 460. Psoriasis Drug Sales: by Type(K Units)
  • Table 461. Psoriasis Drug Sales Biologic Drugs , by Region K Units (2022-2027)
  • Table 462. Psoriasis Drug Sales Small Molecule Systemic Drugs , by Region K Units (2022-2027)
  • Table 463. Psoriasis Drug Sales Tropical Therapies , by Region K Units (2022-2027)
  • Table 464. Psoriasis Drug Sales: by Application(K Units)
  • Table 465. Psoriasis Drug Sales Packaging , by Region K Units (2022-2027)
  • Table 466. Psoriasis Drug Sales Automotive , by Region K Units (2022-2027)
  • Table 467. Psoriasis Drug Sales Building and Construction , by Region K Units (2022-2027)
  • Table 468. Psoriasis Drug Sales: by Route of Administration(K Units)
  • Table 469. Psoriasis Drug Sales Oral , by Region K Units (2022-2027)
  • Table 470. Psoriasis Drug Sales Parenteral , by Region K Units (2022-2027)
  • Table 471. Psoriasis Drug Sales Topical , by Region K Units (2022-2027)
  • Table 472. Psoriasis Drug Sales: by Distribution Channel(K Units)
  • Table 473. Psoriasis Drug Sales Wholesalers , by Region K Units (2022-2027)
  • Table 474. Psoriasis Drug Sales Distributors , by Region K Units (2022-2027)
  • Table 475. Psoriasis Drug Sales Retailers , by Region K Units (2022-2027)
  • Table 476. Psoriasis Drug Sales: by End User(K Units)
  • Table 477. Psoriasis Drug Sales Hospital , by Region K Units (2022-2027)
  • Table 478. Psoriasis Drug Sales Drugs Store , by Region K Units (2022-2027)
  • Table 479. South America Psoriasis Drug Sales, by Country K Units (2022-2027)
  • Table 480. South America Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 481. South America Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 482. South America Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 483. South America Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 484. South America Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 485. Brazil Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 486. Brazil Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 487. Brazil Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 488. Brazil Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 489. Brazil Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 490. Argentina Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 491. Argentina Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 492. Argentina Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 493. Argentina Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 494. Argentina Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 495. Rest of South America Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 496. Rest of South America Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 497. Rest of South America Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 498. Rest of South America Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 499. Rest of South America Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 500. Asia Pacific Psoriasis Drug Sales, by Country K Units (2022-2027)
  • Table 501. Asia Pacific Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 502. Asia Pacific Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 503. Asia Pacific Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 504. Asia Pacific Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 505. Asia Pacific Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 506. China Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 507. China Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 508. China Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 509. China Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 510. China Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 511. Japan Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 512. Japan Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 513. Japan Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 514. Japan Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 515. Japan Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 516. India Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 517. India Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 518. India Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 519. India Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 520. India Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 521. South Korea Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 522. South Korea Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 523. South Korea Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 524. South Korea Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 525. South Korea Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 526. Australia Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 527. Australia Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 528. Australia Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 529. Australia Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 530. Australia Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 531. Rest of Asia-Pacific Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 532. Rest of Asia-Pacific Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 533. Rest of Asia-Pacific Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 534. Rest of Asia-Pacific Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 535. Rest of Asia-Pacific Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 536. Europe Psoriasis Drug Sales, by Country K Units (2022-2027)
  • Table 537. Europe Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 538. Europe Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 539. Europe Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 540. Europe Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 541. Europe Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 542. Germany Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 543. Germany Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 544. Germany Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 545. Germany Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 546. Germany Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 547. France Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 548. France Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 549. France Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 550. France Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 551. France Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 552. Italy Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 553. Italy Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 554. Italy Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 555. Italy Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 556. Italy Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 557. United Kingdom Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 558. United Kingdom Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 559. United Kingdom Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 560. United Kingdom Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 561. United Kingdom Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 562. Netherlands Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 563. Netherlands Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 564. Netherlands Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 565. Netherlands Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 566. Netherlands Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 567. Rest of Europe Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 568. Rest of Europe Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 569. Rest of Europe Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 570. Rest of Europe Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 571. Rest of Europe Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 572. MEA Psoriasis Drug Sales, by Country K Units (2022-2027)
  • Table 573. MEA Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 574. MEA Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 575. MEA Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 576. MEA Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 577. MEA Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 578. Middle East Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 579. Middle East Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 580. Middle East Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 581. Middle East Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 582. Middle East Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 583. Africa Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 584. Africa Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 585. Africa Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 586. Africa Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 587. Africa Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 588. North America Psoriasis Drug Sales, by Country K Units (2022-2027)
  • Table 589. North America Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 590. North America Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 591. North America Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 592. North America Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 593. North America Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 594. United States Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 595. United States Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 596. United States Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 597. United States Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 598. United States Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 599. Canada Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 600. Canada Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 601. Canada Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 602. Canada Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 603. Canada Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 604. Mexico Psoriasis Drug Sales, by Type K Units (2022-2027)
  • Table 605. Mexico Psoriasis Drug Sales, by Application K Units (2022-2027)
  • Table 606. Mexico Psoriasis Drug Sales, by Route of Administration K Units (2022-2027)
  • Table 607. Mexico Psoriasis Drug Sales, by Distribution Channel K Units (2022-2027)
  • Table 608. Mexico Psoriasis Drug Sales, by End User K Units (2022-2027)
  • Table 609. Psoriasis Drug: by Type(USD/Units)
  • Table 610. Research Programs/Design for This Report
  • Table 611. Key Data Information from Secondary Sources
  • Table 612. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Psoriasis Drug: by Type USD Million (2016-2021)
  • Figure 5. Global Psoriasis Drug: by Application USD Million (2016-2021)
  • Figure 6. Global Psoriasis Drug: by Route of Administration USD Million (2016-2021)
  • Figure 7. Global Psoriasis Drug: by Distribution Channel USD Million (2016-2021)
  • Figure 8. Global Psoriasis Drug: by End User USD Million (2016-2021)
  • Figure 9. South America Psoriasis Drug Share (%), by Country
  • Figure 10. Asia Pacific Psoriasis Drug Share (%), by Country
  • Figure 11. Europe Psoriasis Drug Share (%), by Country
  • Figure 12. MEA Psoriasis Drug Share (%), by Country
  • Figure 13. North America Psoriasis Drug Share (%), by Country
  • Figure 14. Global Psoriasis Drug: by Type K Units (2016-2021)
  • Figure 15. Global Psoriasis Drug: by Application K Units (2016-2021)
  • Figure 16. Global Psoriasis Drug: by Route of Administration K Units (2016-2021)
  • Figure 17. Global Psoriasis Drug: by Distribution Channel K Units (2016-2021)
  • Figure 18. Global Psoriasis Drug: by End User K Units (2016-2021)
  • Figure 19. South America Psoriasis Drug Share (%), by Country
  • Figure 20. Asia Pacific Psoriasis Drug Share (%), by Country
  • Figure 21. Europe Psoriasis Drug Share (%), by Country
  • Figure 22. MEA Psoriasis Drug Share (%), by Country
  • Figure 23. North America Psoriasis Drug Share (%), by Country
  • Figure 24. Global Psoriasis Drug: by Type USD/Units (2016-2021)
  • Figure 25. Global Psoriasis Drug share by Players 2021 (%)
  • Figure 26. Global Psoriasis Drug share by Players (Top 3) 2021(%)
  • Figure 27. Global Psoriasis Drug share by Players (Top 5) 2021(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 30. AbbVie (United States) Revenue: by Geography 2021
  • Figure 31. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 32. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 33. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 35. Galderma S.A.(Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Galderma S.A.(Switzerland) Revenue: by Geography 2021
  • Figure 37. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 38. Bristol-Myers Squibb (United States) Revenue: by Geography 2021
  • Figure 39. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 40. Novartis International AG (Switzerland) Revenue: by Geography 2021
  • Figure 41. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 43. Merz Pharma GmbH & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 44. Merz Pharma GmbH & Co. KGaA (Germany) Revenue: by Geography 2021
  • Figure 45. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 46. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2021
  • Figure 47. LEO Pharma A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 48. LEO Pharma A/S (Denmark) Revenue: by Geography 2021
  • Figure 49. GlaxoSmithKline plc (United kingdom) Revenue, Net Income and Gross profit
  • Figure 50. GlaxoSmithKline plc (United kingdom) Revenue: by Geography 2021
  • Figure 51. Global Psoriasis Drug: by Type USD Million (2022-2027)
  • Figure 52. Global Psoriasis Drug: by Application USD Million (2022-2027)
  • Figure 53. Global Psoriasis Drug: by Route of Administration USD Million (2022-2027)
  • Figure 54. Global Psoriasis Drug: by Distribution Channel USD Million (2022-2027)
  • Figure 55. Global Psoriasis Drug: by End User USD Million (2022-2027)
  • Figure 56. South America Psoriasis Drug Share (%), by Country
  • Figure 57. Asia Pacific Psoriasis Drug Share (%), by Country
  • Figure 58. Europe Psoriasis Drug Share (%), by Country
  • Figure 59. MEA Psoriasis Drug Share (%), by Country
  • Figure 60. North America Psoriasis Drug Share (%), by Country
  • Figure 61. Global Psoriasis Drug: by Type K Units (2022-2027)
  • Figure 62. Global Psoriasis Drug: by Application K Units (2022-2027)
  • Figure 63. Global Psoriasis Drug: by Route of Administration K Units (2022-2027)
  • Figure 64. Global Psoriasis Drug: by Distribution Channel K Units (2022-2027)
  • Figure 65. Global Psoriasis Drug: by End User K Units (2022-2027)
  • Figure 66. South America Psoriasis Drug Share (%), by Country
  • Figure 67. Asia Pacific Psoriasis Drug Share (%), by Country
  • Figure 68. Europe Psoriasis Drug Share (%), by Country
  • Figure 69. MEA Psoriasis Drug Share (%), by Country
  • Figure 70. North America Psoriasis Drug Share (%), by Country
  • Figure 71. Global Psoriasis Drug: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • AbbVie (United States)
  • Johnson & Johnson (United States)
  • Bayer AG (Germany)
  • Galderma S.A.(Switzerland)
  • Bristol-Myers Squibb (United States)
  • Novartis International AG (Switzerland)
  • Pfizer Inc. (United States)
  • Merz Pharma GmbH & Co. KGaA (Germany)
  • Bausch Health Companies Inc. (Canada)
  • LEO Pharma A/S (Denmark)
  • GlaxoSmithKline plc (United kingdom)
Select User Access Type

Key Highlights of Report


Sep 2022 170 Pages 84 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Psoriasis Drug Market Quantitative research analysis
Global Psoriasis Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Psoriasis Drug market are AbbVie (United States), Johnson & Johnson (United States), Bayer AG (Germany), Galderma S.A.(Switzerland), Bristol-Myers Squibb (United States), Novartis International AG (Switzerland), Pfizer Inc. (United States), Merz Pharma GmbH & Co. KGaA (Germany), Bausch Health Companies Inc. (Canada), LEO Pharma A/S (Denmark) and GlaxoSmithKline plc (United kingdom), to name a few.
Asia Pacific is dominating the Psoriasis Drug Market.
"Lack of Awareness of benefits of the Psoriasis Drug" is seen as one of the major challenges by many Industry Players of Psoriasis Drug Market
The Psoriasis Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Psoriasis Drug market is expected to see a steady growth rate during projected year 2021 to 2027.

Know More About Global Psoriasis Drug Market Report?

Have a Query? Click Here

Other Related Reports

Depression Drugs Comprehensive Study by Type (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Serotonin...
$ 3750
Ulcerative Colitis Comprehensive Study by Application (Hospital, Drugs Stores), Route of Administration (Oral, Injection), Disease level (Mild, Moderate, Severe), Ulcerative Colitis (Ulcerative proc...
$ 3650
Etoposide Comprehensive Study by Type (Etoposide for Injection, Etoposide for Oral Use), Application (Small Cell Lung Cancer, Testicular Cancer), Distribution Channel (Hospital Pharmacies, Retail Pha...
$ 3350
Soliris Drug Comprehensive Study by Type (Plasma Exchange, Plasma Infusion), Application (PNH, AHUS, HPP, GMG, Other), End-User (Pharmaceutical, Hospital, R&D labs, Others) Players and Region - Globa...
$ 3500
Sugar Sphere Comprehensive Study by Type (Micrometers, Standard spheres), Application (Tablets, Capsules), Form Type (Crystal, Granules) Players and Region - Global Market Outlook to 2029
$ 3500
Aloe Vera Extracts Comprehensive Study by Type (Gel Extracts, Whole Leaf Extracts, Powder, Others), Application (Food & Beverages, Pharmaceutical, Cosmetics, Others), Sales Channel (Online, Offline),...
$ 3800